Q2 2025 Management View Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for ...

Skye Bioscience Inc (SKYE) reports significant advancements in clinical trials and financial stability, despite increased ...

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Skye Bioscience, Inc., a biotechnology company specializing in treatments for obesity and metabolic disorders, announced the launch of its "Anatomy of Progress" video series, showcasing the ...

About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors.

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation ...

About Skye Bioscience Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibrotic processes.

Get the latest Skye Bioscience Inc. R (09R.F) stock news and headlines to help you in your trading and investing decisions.

Skye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion PRESS RELEASE Newsfile May. 15, 2023, 07:00 AM ...

Skye Bioscience, Inc. (NASDAQ:SKYE – Get Free Report)’s stock price rose 24% on Thursday . The company traded as high as $1.81 and last traded at $2.15. Approximately 320,782 shares traded ...

Skye Bioscience, Inc., a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that the safety review committee for its Phase 1 clinical ...

Skye Bioscience, Inc.SKYEand Emerald Health Therapeutics, Inc. EMHTFEMHhave entered into a definitive agreement with respect to a transaction to be completed by way of a plan of arrangement ...